Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting.

IF 17.5 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2026-06-12 DOI:10.1186/s40164-026-00790-4

Shi Feng, Ran Kong, Li Xiao, Xiangxiang Zhou

引用次数: 0

Abstract

Dual-target chimeric antigen receptor T (CAR-T) cell therapy has emerged as a promising strategy to address the key limitations of single-target CAR-T approaches, including antigen heterogeneity and antigen-negative escape. Recent studies have reported rapid progress in the engineering of dual-target CAR-T, incorporating diverse receptor architectures, logic-gated designs, and novel manufacturing platforms. Preclinical data demonstrate improved disease control across B-cell malignancies, acute myeloid leukemia, and autoimmune disease models. Here, we summarize the latest advancements in the preclinical investigations and clinical trials of dual-target CAR-T cell therapy presented at the 2025 ASH annual meeting.

查看原文本刊更多论文

双靶点CAR-T细胞疗法：来自2025年ASH年会的最新消息。

双靶点嵌合抗原受体T （CAR-T）细胞疗法已成为解决单靶点CAR-T方法主要局限性的一种有希望的策略，包括抗原异质性和抗原阴性逃逸。最近的研究报道了双靶点CAR-T工程的快速进展，包括不同的受体结构、逻辑门控设计和新的制造平台。临床前数据显示b细胞恶性肿瘤、急性髓性白血病和自身免疫性疾病模型的疾病控制得到改善。在此，我们总结了在2025年ASH年会上提出的双靶点CAR-T细胞治疗的临床前研究和临床试验的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.